Novavax, Inc. (NVAX) key performance indicators and operating metrics (4 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Research and Development Expenses | 95M | FY2026-Q1 |
| Revenue Related to Sanofi Agreement | 49M | FY2026-Q1 |
| Other Partner Revenue | 11M | FY2026-Q1 |
| R21 Matrix-M Malaria Vaccine Doses Sold Since Launch | 30M | FY2025-Q4 |
Back to NVAX overview · NVAX earnings · NVAX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.